NXTC: NextCure Corp Net earnings per share (EPS TTM)

NextCure (NXTC) - corporate logo

NextCure, Inc. (NXTC) focuses on discovering new pathways to combat resistant tumors within its R&D framework. This daily price chart of the annual EPS TTM on GURU.Markets illustrates profit dynamics, where -8.73 reflects the current value of the metric. Innovations are based on the FIND platform for identifying hidden targets, while strategic alliances with pharma behemoths accelerate the validation of new antibodies.

NXTC NextCure, Inc. Net earnings per share for the last 12 months (07/04/2022 - 11/12/2026)

Summary analytical data breakdowns for NextCure Inc (NXTC)

- share price and expert price forecast:
Stock Quotes NextCure, Inc.|NXTC - Fair Value Consensus
- market capitalization information:
Market Capitalization NextCure, Inc.|NXTC - Company Buyout Price
- business book valuation details:
Net Assets per Single Share NextCure|NXTC - Company Net Assets|Market Value to Book Value Ratio nextcure.com|NXTC - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio NextCure, Inc.|NXTC - Long-Term Debt to Capital|Short-Term Debt to Equity NextCure Corp|NXTC - Company Aggregate Debt|Debt to Book Capitalization Ratio NextCure, Inc.|NXTC - Long-Term Debt|Company Current Liabilities NextCure|Quick Liquidity Indicator nextcure.com
- earnings and multiples data:
NXTC - Profit After Payment of Taxes|Projected Future Earnings NextCure, Inc.|NXTC - Company Value to Net Income|Forward P/E Multiple NextCure|NXTC - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NextCure, Inc.|NXTC - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) NextCure|NXTC - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months nextcure.com|NXTC - Earnings per share trend in current year|Expected earnings per share growth for next year NextCure, Inc.
Fundamental valuation:NXTC - NextCure, Inc.
Flagship merchandise of NextCure Corp

Selecting high-quality issuers is based on analyzing a business's ability to generate real income. Annual net income per share measures the portion of profit attributable to a single security, stripping the financial result of the influence of the total issuance volume. For NextCure, Inc. (NXTC), which is developing unique onco-immunological research, this metric reflects the efficiency of monetizing scientific discoveries. By analyzing the current level of rolling earnings per share, an investor assesses business sustainability. The dynamics of this metric allow for the differentiation of long-term growth from one-time cost reductions.

Main competitors

IBRX: Net earnings per share for the last 12 months|Earnings per share for the trailing year IMCR (immunocore.com)|JANX: Net earnings per share (EPS TTM)|RCUS - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Zymeworks Corp|Net earnings per share for the last 12 months Tango Therapeutics Corp (TNGX)|Earnings per share for the last twelve months Iovance Biotherapeutics (IOVA)|Net earnings per share for the last 12 months immatics.com IMTX|Xencor - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Compass Therapeutics Inc CMPX|REPL - Earnings per share for the last twelve months|LYEL (Lyell Pharma) - Earnings per share for the last 12 months|Innate Pharma S.A. (IPHA) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Pyxis Oncology (PYXS)|Net earnings per share for the last 12 months CGEN|IOBT - Net earnings per share for the trailing year|Net earnings per share for the last 12 months STRO (Sutro Bio)|Earnings per share for the last four quarters INKT|Net earnings per share (EPS TTM) HOWL (Werewolf Therapeutics, Inc.)|Earnings per share for the trailing year IMMX|ALX Oncology Holdings - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months cuebiopharma.com|pdsbiotech.com (PDSB) - Earnings per share for the last twelve months|Sonnet BioTherapeutics Holdings - Earnings per share for the trailing year|MAIA (MAIA Biotechnology) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) liminatuspharma.com|Earnings per share for the last twelve months LAVA Therapeutics N.V. (LVTX)|LPTX: Earnings per one share for the last 12 months|Intensity Therapeutics, Inc. - Net earnings per share for the last 12 months|Sensei Biotherapeutics Inc (SNSE) - Net earnings per one share for the last twelve months|TOVX - Earnings per share for the last twelve months|GRTS (Gritstone bio, Inc.) - Earnings per share for the last 12 months|KA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NexImmune Inc (NEXI)|Net earnings per share for the last 12 months TSBX|Earnings per share for the last 12 months VCNX (Vaccinex Inc)|Net earnings per share for the last 12 months HARP (Harpoon Therapeutics)